Favus M J, Kimberg D V, Millar G N, Gershon E
J Clin Invest. 1973 Jun;52(6):1328-35. doi: 10.1172/JCI107304.
Glucocorticoid administration is known to decrease calcium absorption in vivo and the vitamin D-dependent active transport of calcium by rat duodenum in vitro. The basis for this antivitamin D-like effect of glucocorticoids is unclear. Previous studies in the rat failed to demonstrate an effect of glucocorticoid treatment on the hepatic conversion of the parent vitamin to 25-hydroxycholecalciferol (25-HCC). Moreover, pharmacologic doses of 25-HCC did not restore intestinal calcium transport to normal. The results of these experiments suggested that if indeed glucocorticoids interfere with the metabolism of vitamin D, the step involved must be subsequent to 25-hydroxylation. The present studies demonstrate that the administration of cortisone to vitamin D-deficient rats does not affect the rate of conversion of a physiologic dose of [(3)H]25-HCC to the biologically important metabolite, 1,25-dihydroxycholecalciferol (1,25-DHCC). Furthermore, pretreatment with glucocorticoids affects neither the tissue distribution nor the subcellular localization on or in intestinal mucosal cell nuclei of 1,25-DHCC. Of note is the fact that 1,25-DHCC is currently considered to be the "tissue-active" form of the vitamin in the intestine. Whereas tissues from cortisone-treated animals had increased concentrations of the biologically less active 24,25-DHCC, the physiologic significance of this observation remains unclear. The results of the present studies strongly support the concept that the antivitamin D-like effects of glucocorticoids in the intestine are due to hormonal influences on the biochemical reactions responsible for calcium transport. While the effects of these hormones are opposite in direction to those of vitamin D, they occur by a mechanism that is independent of a direct interaction with either the vitamin or its biologically active metabolites.
已知给予糖皮质激素会降低体内钙的吸收,并在体外降低大鼠十二指肠对维生素D依赖的钙主动转运。糖皮质激素这种类抗维生素D作用的基础尚不清楚。以往对大鼠的研究未能证明糖皮质激素治疗对母体维生素向25-羟胆钙化醇(25-HCC)的肝脏转化有影响。此外,药理剂量的25-HCC并不能使肠道钙转运恢复正常。这些实验结果表明,如果糖皮质激素确实干扰维生素D的代谢,那么所涉及的步骤必定在25-羟化之后。目前的研究表明,给维生素D缺乏的大鼠注射可的松并不影响生理剂量的[(3)H]25-HCC向具有生物学重要性的代谢产物1,25-二羟胆钙化醇(1,25-DHCC)的转化速率。此外,用糖皮质激素预处理既不影响1,25-DHCC在肠道黏膜细胞核上或核内的组织分布,也不影响其亚细胞定位。值得注意的是,1,25-DHCC目前被认为是维生素在肠道中的“组织活性”形式。虽然来自可的松处理动物的组织中生物活性较低的24,25-DHCC浓度有所增加,但这一观察结果的生理意义仍不清楚。目前的研究结果有力地支持了这样一种观点,即糖皮质激素在肠道中的类抗维生素D作用是由于激素对负责钙转运的生化反应的影响。虽然这些激素的作用方向与维生素D相反,但它们的作用机制独立于与维生素或其生物活性代谢产物的直接相互作用。